Compare BridgeBio Pharma Inc (BBIO) vs Upwork Inc (UPWK) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

UPWK trades at $9.67, up 2.65% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 revenue of $191.7 million, at the high end of guidance, and adjusted EBITDA of $64.1 million exceeding outlook, per MarketBeat on August 10, 2026. Valuation ratios appear reasonable with a P/E of 11.93 and P/S of 1.7, while profitability remains strong with a net income margin of 13.81% in 2025.

The outlook is mixed; analyst consensus is 52% buy with no sell ratings, but recent earnings misses and legal investigations pose risks. Revenue growth has slowed to 2.9% year-over-year in 2025, and net cash flow turned negative, indicating potential headwinds. Investors should weigh solid fundamentals against execution challenges and AI-driven market shifts.